. This means that the specificity can reliably be estimated soon after the start of the programme. The specificity rate relates to the number of true negatives to the total number of 'non-cancer'
The aim of screening for breast cancer is to reduce breast cancer mortality. However, this effort should not lead to an excess of false positive screening test results, which invariably involve unnecessary diagnostic work-up. It is therefore important that screening programmes are closely monitored, and have a good system for quality control. In such a system one may distinguish technical aspects (apparatus and the like), and aspects regarding the public and the participants. Witcombe (Witcombe, 1988) even speaks of a licence or accreditation system for radiologists. Because the anticipated effect on breast cancer mortality will probably take 10 years to emerge and will only occur if short term reference values are met, quality parameters have been proposed to be evaluated from the very start of the programme . Among these are the compliance and detection rate, disease stage distribution and interval cancer rate, to be calculated for the initial screening, as well as for the further screening examinations.
Here we would like to introduce additional quality parameters for which the values can be determined even earlier.
The emphasis is laid on potentially harmful effects, in particular the so-called false positive screening results concerning women who have been identified by mammographic screening as suspect of having malignant lesions, and who, after adequate diagnostic assessment, turn out to have no such lesions.
Measures for short-term quality control
For the proposed short term quality control the only information required is the total number of women screened, the number of women who are suspected of having cancer because of the initial mammography (positive screening test), and the number of cancer patients among the positive women. With these basic data three outcome measures can be calculated: the specificity, the positive predictive value and the detection rate. The measures alone do not give any valuable information, but a combination of the three do.
( (Morrison, 1985; Brecht & Robra, 1987 ). However, the underlying incidence is usually unknown, unless information about risk factors among the screenees is gathered.
Reference values
In Figure 1 Screening results of a hypothetical programme with two referral strategies. Creating a reference value for the detection rate is difficult. Day et al. set the numerical value in the first screening round at a minimum of three times the expected incidence in the screened population . If a higher incidence is expected, then the reference value should be set higher accordingly. The magnitude of the incidence can be approximated, if data on the screenees' risk factor profiles are available or can be gathered. (See also the Discussion section). Not only the distribution of risk factors, but also the possibility of overdiagnosis should be considered as an explanation of a high detection rate. The fact that in the Nijmegen (Peeters et al., 1989b) as well as in the Swedish study (Tabafr et al., 1989) no overdiagnosis was claimed to be present, does not mean that this will also apply to new screening centres. If overdiagnosis is suspected, a revision of the histological specimen by an independent panel of pathologists is strongly recommended (Beahrs & Smart, 1979 and of large numbers of 'tumour-negative biopsies'. In screening parlance; in the first screening strategy the emphasis was laid on a high sensitivity for the detection of early carcinomas. The second strategy loosens this attitude in order to improve the specificity.
As can be seen in Figure 1 the specificity in Strategy 1 is 96.0%, which is lower than the weighted sum of the agespecific reference value (99.2%, for age-distribution 2:2:1). This is also true for the PV+ (11.4% vs 40%). From this information it can be concluded that the number of false positives in this screening set-up is too high and hence unacceptable. The detection rate in Strategy 1 turned out to be the same as the expected detection rate, based on the agespecific rates in Table I . But because of the different invitation set-up (own initiative vs personal invitation) it is not known whether the age-specific detection rates would be different. It may well be that due to selection the expected rates in this screening population should accordingly be higher.
As has been said, the screening strategy is changed in order to reduce the numbers of false-positives. The outcomes of this second strategy show that the quality of the screening has improved indeed. The specificity has risen to 99.4%, which is higher than the reference value. The same goes for the predictive value: 48.5%. The conclusion can be that the number of false positives is acceptable now. In general, both the specificity and the sensitivity rate should be improved simultaneously through special training facilities, and not just by loosening the criteria for referral. The latter will only increase the specificity, and may cause a lower sensitivity and thus increase the number of women with a false negative result, i.e. interval carcinomas. The higher detection rate in Strategy 2, compared to Strategy 1 and the reference value, reassures us that Strategy 2 will not cause a higher number of interval carcinomas. In fact, the high detection rate in Strategy 2 reduces the chance of a large number of false negatives.
Applicability across programmes
A great variety of breast cancer screening programmes exists across Great Britain, other Western European countries, the USA and Canada. Programmes differ in screening examination, assessment procedure and screening frequency. All these factors bear on the proposed outcome measures specificity, predictive value and detection rate. The screening test itself does not conclusively determine the presence or absence of the disease, but merely sorts the screened people into testpositives and test-negatives, i.e. women who are or are not suspected of having breast cancer, on the basis of their initial mammography, although additional views may be required to define the nature of an artefact or to compensate for a technically inadequate mammogram. The test-positive subjects then need to undergo diagnostic tests to find out whether or not they do have breast cancer. Among these are complete or sophisticated mammography, clinical examination, fine needle aspiration cytology, ultrasonography and biopsy. The proposed outcome measures have been determined on the basis of the initial mammographic screening test (applied to all women participating in the programme), and not to the diagnostic tests assessing the abnormality suspected of representing breast cancer. The absolute and relative numbers of false-positive subjects are either a reflection of 'aggressive' screening with the intention of attaining high sensitivity, or a reflection of poor screening performance, maybe both. When the attitude is to achieve high sensitivity on account of large numbers of falsepositives, the proposed reference values should be adjusted, as is done in Table II for a range of specificity rates.
When, for instance, a 95% specificity rate is considered acceptable, then at least a 10% PV+ and a 5.8/1000 detection rate should be observed in the programme; if not, too few preclinical carcinomas have been detected.
One would like to know what reference values are appropriate in successive screening rounds. Usually, mass screening is carried out at regular intervals, mainly of 2 or 3 years. As regards the interval, one should not simply assume that the specificity, PV+ and detection rate will remain constant at successive screens. The detected cases in the next rounds comprise new developed cases plus cases missed at the previous screening, minus the cases that surfaced clinically between the two screenings. As empirically the detection rate in the first screening round was set at three times the numerical value of the expected incidence, the detection rate in the second screening in a programme with a 2-year screening interval is equal to 50% of the first screening detection rate, and 65% in a programme with a 3-year interval. The specificity will usually increase because most of the systematic false-positive results will occur at the first screening and not the next ones. Further, in the subsequent screening rounds the mammograms of the previous screening examinations are available, and the development of mammographical signs can be interpreted longitudinally. The PV+ tends to remain fairly stable, unless major improvements in sensitivity as well as specificity have taken place.
Discussion
The quality required in a screening centre must be evaluated as soon as possible after the start of a programme. The proposed method for short term quality control is summarised in Figure 2 . Only if all three control measures are met or if the rates actually exceed the reference values, there is no reason to make improvements. In all populations breast cancer is a rare disease. For example, the prevalence in the self-selected population of a London screening centre was 14 per 1,000 (Chamberlain et al., 1984) . In the Nijmegen screening population the prevalence was 5.4 per 1,000. The question is to what extent differences of this magnitude in the rare disease prevalence will influence the control measurements. If a high risk population is screened the PV+ will be higher just because the prevalence is higher. This means that the reference value could be set higher and accordingly the proportion of false positives would be lower. In considering the detection rate it is of course necessary to have some knowledge of the expected prevalence. This is possible by looking at the prevalence of risk factors in the screening population. This is especially important for screening high risk populations or self-selected populations. For illustrative purposes, suppose among 10,000 screenees 100 women will have a false positive screening result, but the detection rate of detectable preclinical disease varies: 5 per 1,000, 10 per 1,000 and 15 per Figure 2 Short term quality control: overview.
Screening-1,000, respectively. Then PV+ varies accordingly: 33.3%, 50% and 60%. One might be guided by published regression coefficients generated through multivariate logistic analyses (Alexander et al., 1988) , and calculate the underlying incidence rate. This rate is multplied by three to estimate the expected detection rate in the initial screening examination. If the observed detection rate is still too high, then the histological specimen should be reviewed by an independent panel, especially the cases of the 'borderline' category (Elston, 1984) .
The described method of short term quality control should make it possible for newly started screening centres to improve and optimise the screening performance at an early stage, thus achieving a high quality screening as soon as possible. When adjustments are necessary, a way of achieving this is by reviewing false positive mammograms, extra training of the radiologists and checking the technical quality of the mammograms.
Performing short term quality control is clearly not a substitute for evaluating the screening at a later stage. However, the presented reference values are proposals based on data from programmes with an observed breast cancer mortality reduction and with acceptable numbers of false-positive screening results, together with a high attendance rate: 80-90%. Of course, before starting a programme other reference values may be chosen, presumably based on local effectiveness considerations (Knox, 1988) or even cost-effectiveness outcomes (Van der Maas et al., 1989) , such as recently presented.
Our suggested reference value of 99.2% for the specificity, for instance, might look too high. It implies that less than 1% of the breast cancer free population is called back (referred) for further diagnostic evaluation. The Forrest report (Working Party, 1986) indicated that the referral rate, might run up to 10% of the population. The explanation must be the wish to achieve a nearly perfect sensitivity. This goal, however, seems hard to attain, because a substantial number of interval cancers are radiographically occult, even at the time of diagnosis (Peeters et al., 1989c) . Therefore, aiming to achieve high specificity does not necessarily mean a low sensitivity rate and a smaller breast cancer mortality reduction as a consequence.
